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Fetal abnormality is a major cause of termination of pregnancy and preservation of the fetus is important for conﬁrmation of
the diagnosis. Various regimes have been reported for termination of pregnancy for fetal abnormality in the ﬁrst and the second
trimesters. In this paper, we compare those regimes that allow preservation of the fetus, in terms of the eﬃcacy in expulsion of the
fetus, the factors and the side eﬀects.
1.Introduction
Fetal abnormality is known to be a major cause of perinatal
mortality. Termination of pregnancy for fetal abnormalities
signiﬁcantly decreases perinatal mortality resulting from
birth defects [1, 2]. Fetal morphological anomalies (without
chromosomal anomalies) and chromosomal anomalies form
the main ground for termination of pregnancy in 39%
and 35% of cases respectively in a study by Guillem et al.
[3] and 47% and 33%, respectively, in another study by
Ramalho et al. [4]. For morphological anomalies identiﬁed
by ultrasound with no evidence for abnormal karyotype, it
is estimated that autopsy adds information that leads to a
reﬁnement of the risk of recurrence in 27% and revision
to a higher risk of 1 in 4 in 8% of cases [5]. In another
study, complete correlation between ultrasound ﬁndings
and pathological examination is found in only 61.1% of
autopsies. This highlights the importance of pathological
examination for conﬁrmation [4]. When surgical termina-
tion is employed for fetal abnormality, an intact fetus is
not obtained. Pathological examination of fetal parts by use
of radiography, gross dissection, microscopic examination,
and/or cell culture for karyotyping or biochemical analysis
may detect a major abnormality in 92%, and in 46%
a speciﬁc diagnosis was obtained only from pathologic
examination [6]. As there is a trend for prenatal diagnosis
to take place earlier in pregnancy, largely as a result of ﬁrst
trimester ultrasound screening [7], more pregnancies are
expected to be terminated in the ﬁrst trimester. Preservation
of the whole fetus is possible with medical termination in
the ﬁrst trimester [8–11] although pathological examination
is usually technically more diﬃcult in these specimens [12].
In this paper, we compare the methods and outcome for
termination of pregnancy for fetal abnormality in the ﬁrst
and second trimesters, respectively, especially those that
potentially allow preservation of the fetus for pathological
examination.
2. Method andMaterials
Medline was searched for induced abortion (MeSH) and
prenatal diagnosis, and also for induced abortion (MeSH)
for fetal abnormality. The ﬁrst search resulted in 604 hits
and the second 29 hits. The papers in English language
were reviewed for any description and outcome analysis on
termination of pregnancy for fetal abnormality in the ﬁrst
and second trimesters. Further search was performed by
hand from related or cited articles.
3. Results
3.1.TerminationintheSecondTrimesterforFetalAbnormality.
Kanhai and Keirse studied the use of low dose sulprostone
in termination of pregnancy for fetal abnormality between2 ISRN Obstetrics and Gynecology
16 and 35 weeks in 32 pregnancies [13]. In 31 pregnancies,
intravenous infusion of 0.5mg sulprostone per minute was
given for 60 minutes followed by 1mcg per minute until
the fetus was expelled. All patients delivered vaginally. 84%
delivered within 36 hours. The median induction-expulsion
interval was 23 hours. In one patient, 0.5mg of endocervical
prostaglandin E2 was given followed by infusion of up
to 2mcg sulprostone per minute. This patient delivered
vaginally after 74 hours. Induction-expulsion intervals were
not associated with gestational age. Manual removal of
placenta was required in 28% of cases. Median blood loss
was 100mLs. 9% patients lost more than 1000mLs. Six out
of 32 patients (18%) did not require analgesic and 6 patients
(18%) experience gastrointestinal side eﬀects.
Hinshaw et al. studied the use of 600mg mifepris-
tone priming followed by misoprostol 36–48 hours later
(800mcg vaginally then 400mcg orally 3-hourly, maximum
4 doses) in 20 cases of mid-trimester termination for fetal
abnormality [14]. All patients aborted within 15 hours.
The median induction-to-abortion interval was shorter for
parous women compared with nulliparous women (5.5
versus 11.25 hours). Medical termination of pregnancy was
complete in 95% with only one patient requiring uterine
evacuation. Intramuscular opiates were administered in 12
(60%) and 2 other required nonnarcotic analgesics alone
(10%). The remaining 30% did not require analgesia. Ten
women (50%) developed nausea and 8 (40%) had vomiting.
Four patients (20%) noted diarrhoea. There was no case of
infection and 9 (45%) developed prostaglandin-associated
pyrexia (<38◦C).
Dickinson and Evans compared regimes incorporating
oral or vaginal misoprostol in a randomized trial for ter-
mination of pregnancy at 14–26 weeks for fetal abnormality
[15]. They found that the use of vaginal misoprostol 400mcg
every 6 hours (n = 2 8 )w a s1 . 9t i m e sm o r el i k e l yt or e s u l ti n
delivery within 24 hours compared with oral administration
(400mcg orally every 3 hours, n = 29) (rate of delivery
86% versus 45%). Moreover, no further intervention was
required to eﬀect delivery 48 hours after commencement of
misoprostol in the vaginal administration group compared
with 20.7% in the oral group. The former group had less
vomiting score and the latter group had more diarrhoea.
There was no diﬀerence in women’s perception of the
termination process.
Dickinson reviewed the outcome of termination of preg-
nancy with misoprostol at 14–28 weeks for fetal abnormality
in 101 women with 1 to 3 prior Caesarean section(s) against
609womenwithunscarreduterusinacohort(mediangesta-
tion 19.4 versus 19.3 weeks) [16]. Despite that the former
group consisted of older women with increased parity, there
was no statistical signiﬁcant diﬀerence in abortion duration
orcomplicationsincludingbloodlossandbloodtransfusion.
There was no case of uterine rupture or hysterectomy.
The addition of mifepristone for priming (200mg 24–48
hours prior, n = 199) to misoprostol alone (400mcg every 6
hours, maximum 48 hours, n = 189) in a sequential cohort
for termination at 14–24 weeks (median 19 weeks) was
found to reduce the median abortion duration from 15.5
to 8.6 hours and the duration of hospitalisation from 31.5
to 27.2 hours [17]. Increasing gestation was associated with
a longer duration of termination regardless of the regime
used (6.5 hours for 14–18 weeks and 10.5 hours for 20–28
weeks in the mifepristone priming group). Complications
including fever, blood loss, rate of blood transfusion (2%
versus 3.7%) and the rate of placental retention requiring
removal in theatre (25.6% versus 24.5%) was not statistically
signiﬁcantly diﬀerent. In both groups, about 10% of women
had blood loss of ≥500mLs. There was no case of uterine
rupture or hysterectomy in this series.
The factors inﬂuencing the duration of pregnancy ter-
mination with vaginal misoprostol (400mcg vaginally 6-
hourly) for fetal abnormality at gestational age ≥13 weeks
were studied in a consecutive case series involving 1066
women [18]. The median gestation at termination was 19.5
weeks and the median abortion interval was 16.1 hours.
Lowermaternalage(medianduration17.6versus15.2versus
13.6 hours for age <30 versus 30–39 versus >40 years, P<
0.001), nulliparity (median duration 19 versus 14.3 hours for
multiparous women, P<0.001), and increasing gestation
(medianduration13versus17.8hours,at<16and>20weeks
resp., P<0.001) were associated with abortion prolonga-
tion. Multiparous women also required less misoprostol to
eﬀect delivery. 164 (15.4%) women had at least one prior
Caesarean section (all lower segment) and 25% had more
than one Caesarean scar. There was one uterine rupture in
a woman with 2 previous Caesarean sections. The speciﬁc
fetal anomaly did not inﬂuence the abortion duration after
controlling for gestation, age, and parity, with the exception
of musculoskeletal abnormalities (P = 0.03). Although pro-
longed induction was noted in termination of pregnancy
with fetal neural tube defect or hydrocephalus in a previous
study [19], it was not conﬁrmed in this study. Placental
retention occurred in 31.1% of cases, being 53.2% at <16
weeks gestation compared with 40.6% and 12.8% at 16–19
weeksand ≥20weeks,respectively.Overallbloodlossandthe
need for transfusion increased with placental retention. In 5
cases (0.47%) alternative methods were required to achieve
termination of pregnancy either due to failed misoprostol
induction (n = 4) or uterine rupture (n = 1).
Loetal.retrospectivelycomparedtheeﬀectofgestational
age on the outcome of 280 second-trimester termination of
pregnanciesforfetalabnormalitiesusingvaginalmisoprostol
400mcg 3-hourly, up to 5 doses in 24 hours [20]. It was
noted that termination before 17 weeks was associated with
higher chance of incomplete abortion (43% versus 25%, OR
2.2) and lower chance of experiencing signiﬁcant side eﬀects
comparedtoterminationafter20weeks(2%versus11%).All
cases aborted within 72 hours, with 83.9% in the ﬁrst day.
In a retrospective study involving termination of 184
singleton pregnancy for fetal abnormalities in late ﬁrst and
second-trimester termination of pregnancy (11–24 weeks),
prostaglandin derivatives, either 200mcg misoprostol (orally
and vaginally at the same time) or 1mg gemeprost (4–6
hourly), was used in patients without uterine scar. 1mg
gemeprost or 0.5mg dinoprostone 4–6 hourly was used in
cases of previous Caesarean section. The median induction-
expulsion interval was 18 hours and the interval was longer
than 24 hours in 32.1%. Gestational age and past history ofISRN Obstetrics and Gynecology 3
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spontaneous delivery were signiﬁcant contributing factors to
induction interval of ≤24 hours [21].
T h e s es t u d i e sa r es u m m a r i s e di nTable 1.
In one study, the eﬀect of feticide on the duration of
labourinductionwasexaminedretrospectivelyandtherewas
no signiﬁcant diﬀerence noticed in the outcome except that
the group with feticide tend to have more procedure in the
form of manual extraction of placenta or uterine curettage
or both (82.9 versus 65.6%, P = 0.01) [22]. This study diﬀers
fromtheotherstudiesaboveinthatitisnotstratiﬁedaccord-
ing to the method of termination but rather whether feticide
was performed or not. It is therefore not included in the
summary table.
There were 2 studies that stratify the outcome according
to the type of fetal abnormality and they are also excluded in
this review [19, 23].
3.2. Termination in the First Trimester. T h e r ei sn os p e c i ﬁ c
study on termination of pregnancy for fetal abnormality
in the ﬁrst trimester although case reports have indicated
success with the use of prostaglandin vaginally [8–11].
In a Cochrane systemic review, a comparison was made
between medical and surgical methods for ﬁrst trimester
termination of pregnancy [24]. Four diﬀerent interventions
were compared: prostaglandin alone, mifepristone alone,
and miferistone/misoprostol and methotrexate/misoprostol
versus vacuum aspiration. These trials were not for fetal
abnormality alone. The eﬃcacy rates were ranging between
76% and 97.2% for medical (the lowest being prostaglandin
alone group) and between 94 and 100% for surgical abor-
tions in the individual trials. The combination of mifepris-
tone followed by a prostaglandin is the most common used
medical method for ﬁrst trimester abortion. There was no
statistical signiﬁcant diﬀerence in the blood loss between
mifepristone/misoprostol group versus vacuum aspiration
although longer duration of bleeding, more vomiting and
diarrhoea, more pain following the procedure and more un-
completed abortion (OR 2.1, not reaching statistic signif-
icance) was noted with the former. More patients in the
surgical termination group (79%) preferred to have the same
method in the future compared to the medical group (70%).
However, the results were derived from small trials. There is
inadequate evidence to comment on the acceptability and
side eﬀects of medical compared to surgical ﬁrst-trimester
abortions.
In another Cochrane review on medical methods for ﬁrst
trimester abortion, combined regimens are noted to be more
eﬀective than single agents [25]. Misoprostol vaginally is
more eﬀective than orally and the dosage can be lowered to
200mg in combined regimen.
In cervical preparation for ﬁrst trimester surgical abor-
tion, meﬁpristone 200mg 24 hours prior to the procedure
has superior results when compared to misoprostol 600mg
given sublingually 2-3 hours prior to procedure [26]. Geme-
frost had similar eﬀect as laminara tents.
4. Discussion
The study by Kanhai and Kierse [13] illustrated the possible
transference of methods of termination of pregnancy for
other indications, for example fetal death, to fetal abnor-
malities. It appears that the methods used for termination
of pregnancy in the ﬁrst and second trimesters are also
transferrable [14, 15, 17, 25–27].
The trend now is to administer prostaglandin orally
or vaginally. Vaginal prostaglandin is shown to be more
eﬀective than oral. Priming with meﬁpristone gives better
results. The eﬀects of gemeprost and mifepristone on the
mechanical properties of the cervix prior to ﬁrst trimester
termination of pregnancy had been studied in the past it
was shown that both were similarly eﬀective in increasing
cervical distensibility. However cervical dilatation was easier
with a 48 hour regimen of mifepristone than with gemeprost
[27]. Therefore a combination of mifepristone and vaginal
prostaglandin appears to be the most eﬀective method.
When it comes to ﬁrst trimester termination of preg-
nancy for fetal abnormality, there are 2 main areas of
concern:
(1) How certain are we of the diagnosis and the severity
of aﬀection?
(2) Whatarethenaturalhistoryandthespontaneousloss
rate of the condition?
Understanding of embryonic development and transitory
changes is required to avoid false positives. Moreover there
are certain limitations to ﬁrst trimester scans [12]. In
termination of pregnancy up to 9 weeks for social reasons,
pathological examination revealed that 19% had a structural
abnormality and 34% of cases might have ended in a failed
pregnancy [28]. In chromosomal abnormalities diagnosed at
11–14 weeks, it is estimated that 46% of cases of Trisomy
21 and 83% of cases of trisomy 18 and 13 will result in
intrauterine death [12].
Anotherareathatmaybeexploredonisthepsychological
eﬀects of termination of pregnancy. This is outside the scope
of the present review.
5. Conclusion
Termination of pregnancy for fetal abnormality in the
ﬁrst and second trimesters is feasible with those methods
that are used for termination of pregnancy in general
and yet preserving the fetus for pathological examination.
The combination of meﬁpristone and vaginal misoprostol
appears to give the best results. Termination at an earlier
gestation is associated with a shorter duration of induction
but an increased chance of incomplete abortion.
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